logo
Book a meeting
Calcilytix Therapeutics

Calcilytix Therapeutics

Biotechnology, 421 Kipling St, Palo Alto, California, 94301, United States, 11-50 Employees

calcilytix.com

  • LinkedIn

phone no Phone Number: 16*********

Who is CALCILYTIX THERAPEUTICS

Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our...

Read More

lock icon Get Full Access
map
  • 421 Kipling St, Palo Alto, California, 94301, United States Headquarters: 421 Kipling St, Palo Alto, California, 94301, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 87

checked-icon Does something look wrong? Fix it. | View contact records from CALCILYTIX THERAPEUTICS

Calcilytix Therapeutics Org Chart and Mapping

Employees
Lyndsay Smith

Lyndsay Smith

Associate Director, Corporate Development

See Full Org Chart arrow
email-formate-icon
View Email Formats for Calcilytix Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Calcilytix Therapeutics

Answer: Calcilytix Therapeutics's headquarters are located at 421 Kipling St, Palo Alto, California, 94301, United States

Answer: Calcilytix Therapeutics's phone number is 16*********

Answer: Calcilytix Therapeutics's official website is https://calcilytix.com

Answer: Calcilytix Therapeutics's revenue is $50 Million to $100 Million

Answer: Calcilytix Therapeutics's SIC: 87

Answer: Calcilytix Therapeutics has 11-50 employees

Answer: Calcilytix Therapeutics is in Biotechnology

Answer: Calcilytix Therapeutics contact info: Phone number: 16********* Website: https://calcilytix.com

Answer: Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access